1

2
Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda: 4′-Substituted nucleoside derivatives as inhibitors of HCV RNA replication. Roche Palo Alto, Brian L Buckwalter, October 27, 2009: US07608601 (12 worldwide citation)

The present invention relates to the use of nucleoside derivatives of formula I wherein B signifies a 9-purinyl residue B1 of formula or a 1-pyrimidyl residue B2 of formula wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof; for the treatment of ...


3
Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda: 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication. Roche Palo Alto, Brian L Buckwalter, December 6, 2011: US08071567 (12 worldwide citation)

The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.


4
Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Nobuo Shimma, Takuo Tsukuda: 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication. Roche Palo Alto, Brian L Buckwalter, March 29, 2011: US07915232 (11 worldwide citation)

The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof which inhibit HCV polymerase and are useful for treating a patient suffering from a HCV infection and to pharmace ...


5
Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda: 4-Substituted nucleoside derivatives as inhibitors of HCV RNA replication. Roche Palo Alto, Patent Law Dept M S A2 250, December 30, 2004: US20040266722-A1

The present invention relates to the use of nucleoside derivatives of formula I 1 wherein B signifies a 9-purinyl residue B1 of formula 2 or a 1-pyrimidyl residue B2 of formula 3 wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof; for the treatm ...


6
Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda: 4-substituted nucleoside derivatives as inhibitors of HCV RNA replication. Roche Palo Alto, Patent Law Dept M S A2 250, December 25, 2003: US20030236216-A1

The present invention relates to the use of nucleoside derivatives of formula I 1 wherein B signifies a 9-purinyl residue B1 of formula 2 or a 1-pyrimidyl residue B2 of formula 3 wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof; for the treatm ...


7
Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Nobuo Shimma, Takuo Tsukuda: 4-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication. Rohan Peries Patent Law Department M S A2 250, Roche Bioscience, January 7, 2010: US20100004192-A1

The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.


8
Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda: 4-substituted nucleoside derivatives as inhibitors of hcv rna replication. Rohan Peries, Patent Law Department M S A2 250, January 7, 2010: US20100003213-A1

The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.


9
Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda: 4-substituted nucleoside derivatives as inhibitors of hcv rna replication. February 9, 2012: US20120034184-A1

The present invention relates to the use of nucleoside derivatives of formula I wherein B signifies a 9-purinyl residue B1 of formula or a 1-pyrimidyl residue B2 of formula wherein the symbols are as defined in the specification,and of pharmaceutically acceptable salts thereof; for the treatment of ...


10
4-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION. Roche Palo Alto, September 12, 2013: US20130237491-A1

The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.